{
    "nct_id": "NCT02975934",
    "official_title": "TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency",
    "inclusion_criteria": "* Be 18 years old at the time the informed consent is signed\n* Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate that is metastatic\n* Be surgically or medically castrated, with serum testosterone levels of â‰¤ 50 ng/dL (1.73 nM)\n* Be eligible for treatment with physician's choice of comparator treatment (abiraterone acetate, enzalutamide or docetaxel)\n* Experienced disease progression after having received 1 prior next generation androgen receptor-targeted therapy\n* Have a deleterious mutation in a BRCA1/2 or ATM gene\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active second malignancy, with the exception of curatively treated non melanoma skin cancer, carcinoma in situ, or superficial bladder cancer\n* Prior treatment with any PARP inhibitor\n* Prior treatment with chemotherapy for metastatic castration-resistant prostate cancer\n* Symptomatic and/or untreated central nervous system metastases\n* Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of study drug",
    "miscellaneous_criteria": ""
}